drugset / Trial / NCT02883439
Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate
Withdrawn
University Hospital, Ghent
MEDA Pharma GmbH & Co. KG · collabUniversity of Wuerzburg · collab
RandomizedSingle-groupOpen-labelSupportive care
Summary
The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.
Timeline
- Start
- 2016-08
- Primary completion
- 2020-03
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DYMISTA® | Unknown | 137 unknown | Intranasal |
| Comparator | Fluticasone propionate | Other / unclassified | — | Intranasal |
Indications
No indication recorded.